| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001245 |
Purpose
This study will explore faster and easier ways to detect infection with the intestinal parasite Strongyloides stercoralis and learn more about the conditions under which it causes serious disease. Ordinarily, the Strongyloides helminth (type of intestinal worm) causes only few, if any, symptoms, but in people with weakened immunity it may be very serious, and even deadly.
People between 5 and 80 years of age with known or suspected S. stercoralis infection, or infection with another helminth, such as filariasis, that might cause a cross-reaction with S. stercoralis may be eligible for this study.
Participants found to be infected with S. stercoralis will be treated with ivermectin, thiabendazole, or albendazole. In addition, they will undergo the following tests and procedures:
| Condition |
|
HIV Infection Nematode Infection Strongyloidiasis |
| MedlinePlus related topics: | AIDS Allergy |
| Study Type: | Observational |
| Official Title: | Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis |
| Estimated Enrollment: | 650 |
| Study Start Date: | August 1989 |
This study is directed to patients with known or suspected Strongyloides stercoralis infection because it is a relatively common parasitic infection, even in the United States. It is difficult to diagnose, and efficacy of treatment is difficult to evaluate. Some infected individuals can develop serious even fatal, disease under certain conditions of immunosuppression. Because newer diagnostic methods are needed to diagnose this infection, we have developed new diagnostics that will be evaluated in comparison to more standard diagnostic tests. Serum and cells will also be collected from patients on this protocol to understand the cellular and humoral response to the parasite and its antigens. All subjects proven to have Strongyloides stercoralis infection will be treated with standard therapy and followed to assess both the efficacy of treatment and the changes in humoral and cellular immune responses induced by treatment.
Eligibility
| Ages Eligible for Study: | 8 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Age of 5 to 80 years and of either sex.
Access to primary medical care provider outside of the NIH
Ability to give written informed consent (for adults) and parental consent (for those under 18)
Presence of known or suspected infection with Stronglyloides stercoralis, such as significant peripheral blood eosinophilia (greater than 1000 eosinophils/mm(3)) for which no other cause is apparent.
Willingness to participate and provide blood for in vitro assays and serum storage.
EXCLUSION CRITERIA:
Less than 5 years of age
Pregnancy is not a criterion for exclusion.
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Maryland | |||||
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting | ||||
| Bethesda, Maryland, United States, 20892 | |||||
| Brazil | |||||
| Federal University of Bahia | Recruiting | ||||
| Bahia, Brazil | |||||
More Information
NIH Clinical Center Detailed Web Page
|
| Study ID Numbers: | 890174, 89-I-0174 |
| First Received: | November 3, 1999 |
| Last Updated: | August 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001245 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|
|
